Castle Biosciences (NASDAQ:CSTL) Earns Outperform Rating from Analysts at Svb Leerink

Svb Leerink started coverage on shares of Castle Biosciences (NASDAQ:CSTL) in a research report report published on Monday, BenzingaRatingsTable reports. The firm issued an outperform rating and a $28.00 price target on the stock. Svb Leerink also issued estimates for Castle Biosciences’ Q2 2019 earnings at ($0.44) EPS, Q3 2019 earnings at ($0.27) EPS, Q4 2019 earnings at ($0.28) EPS, FY2019 earnings at ($1.23) EPS, Q1 2020 earnings at ($0.30) EPS, Q2 2020 earnings at ($0.36) EPS, Q3 2020 earnings at ($0.30) EPS, Q4 2020 earnings at ($0.33) EPS, FY2020 earnings at ($1.29) EPS and FY2021 earnings at ($0.42) EPS.

A number of other research firms have also recently commented on CSTL. Robert W. Baird initiated coverage on shares of Castle Biosciences in a research note on Monday. They set an outperform rating and a $27.00 target price on the stock. Leerink Swann initiated coverage on shares of Castle Biosciences in a research note on Monday. They set an outperform rating and a $28.00 target price on the stock. Finally, Canaccord Genuity initiated coverage on shares of Castle Biosciences in a research note on Monday. They set a buy rating and a $26.00 target price on the stock. Five equities research analysts have rated the stock with a buy rating, Castle Biosciences currently has an average rating of Buy and a consensus target price of $26.80.

NASDAQ CSTL opened at $22.75 on Monday. Castle Biosciences has a 12 month low of $17.11 and a 12 month high of $24.75.

In related news, major shareholder Mgc Venture Partners 2013 Gp, acquired 312,500 shares of Castle Biosciences stock in a transaction dated Monday, July 29th. The shares were purchased at an average price of $16.00 per share, for a total transaction of $5,000,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David S. Kabakoff acquired 62,500 shares of Castle Biosciences stock in a transaction dated Monday, July 29th. The shares were bought at an average price of $16.00 per share, for a total transaction of $1,000,000.00. The disclosure for this purchase can be found here.

About Castle Biosciences

Castle Biosciences, Inc, a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue.

See Also: Overbought

Analyst Recommendations for Castle Biosciences (NASDAQ:CSTL)

Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.